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ABSTRACT 
The small ubiquitin-like modifier 2 (SUMO-2) is required for survival when cells are exposed to 
treatments that induce proteotoxic stress by causing the accumulation of misfolded proteins. 
Exposure of cells to heat shock or other forms of proteotoxic stress induces the conjugation of 
SUMO-2 to proteins in the nucleus. Here, we investigated the chromatin landscape of SUMO-2 
modifications in response to heat stress. Through chromatin immunoprecipitation assays coupled 
to high-throughput DNA sequencing and with mRNA sequencing, we showed that in response to 
heat shock, SUMO-2 accumulated at nucleosome-depleted, active DNA-regulatory elements, 
which represented binding sites for large protein complexes and were predominantly associated 
with active genes. However, SUMO did not act as a direct transcriptional repressor or activator 
of these genes during heat shock. Instead, integration of our results with published proteomics 
data on heat shock–induced SUMO-2 substrates supports a model in which the conjugation of 
SUMO-2 to proteins acts as an acute stress response that is required for the stability of protein 
complexes involved in gene expression and posttranscriptional modification of mRNA. We 
showed that the conjugation of SUMO-2 to chromatin-associated proteins is an integral 
component of the proteotoxic stress response, and propose that SUMO-2 fulfills its essential role 
in cell survival by contributing to the maintenance of protein complex homeostasis. 
 
INTRODUCTION 
Small ubiquitin-like modifiers (SUMOs) are small proteins that are covalently conjugated to 
various target proteins and thus influence a broad range of biological functions. Three SUMO 
paralogs, termed SUMO-1, SUMO-2, and SUMO-3 are present in higher eukaryotes. Based on 
structural and functional characteristics, SUMO-2 and SUMO-3 are collectively referred to as 
SUMO-2/3 to distinguish them from SUMO-1. SUMO conjugation involves an E1 activating 
enzyme SUMO-activating enzyme subunit 1/2 (SAE1/SAE2) and the SUMO E2 conjugating 
enzyme (UBC9), which catalyzes the formation of an isopeptide bond between the C-terminus of 
SUMO and the ε-amino group of the target lysine, which is often located within a SUMOylation 
consensus motif ΨKxE (Ψ, a hydrophobic amino acid; K, lysine; x, any amino acid residue; E, 
glutamate). A number of E3 ligases, including members of the protein inhibitor of activated 
STAT protein (PIAS) family, chromobox protein homolog 4 (CBX4), and Ran-binding protein 2 
(RanBP2), facilitate the UBC9-dependent conjugation of SUMO to target proteins (1). SUMO 
conjugation is a highly dynamic process and can be reversed through the action of SUMO 
proteases (SENPs). By catalyzing the cleavage of SUMO molecules at a specific C-terminal 
sequence, SENPs are responsible for maturation of SUMO precursor molecules, deconjugation 
of SUMO from substrates, and depolymerization of SUMO chains (2). 
 
SUMO paralogs display a certain degree of functional redundancy and substantial overlaps in 
substrate specificities (3). Yet, paralog-specific characteristics have been ascribed to SUMO-1 
and SUMO-2/3. SUMO-2 and SUMO3 contain a SUMO consensus modification motif that 
enables self-modification and the formation of SUMO chains (4). Incorporation of SUMO-1 into 
these polymers in vivo appears to cap SUMO-2/3 chains (5). Noncovalent binding of SUMO to 
proteins containing SUMO interaction motifs (SIMs) enables SUMO chains to act as platforms 
that mediate protein-protein interactions and downstream signaling events (6, 7). SUMO is 
essential for normal cell function in most eukaryotes (8-12). Although abrogation of UBC9-
dependent SUMOylation leads to early embryonic lethality in mice, knockout studies suggest 
that SUMO-2/3 can functionally compensate for the loss of SUMO-1 (12-14). Modification by 
SUMO-2/3 and SUMO chain formation can be rapidly induced by proteotoxic stress, including 
heat and hyperosmotic and oxidative stress, resulting from the accumulation of unfolded or 
damaged proteins. Heat shock (HS)-induced SUMO conjugation is well-conserved across 
species and has cytoprotective functions (15-22). 
 
Proteotoxic stress is a threat to cellular homeostasis and is implicated in the development of 
many age-associated diseases associated with neurodegeneration. The HS response (HSR) 
enables cells to adapt to and survive proteotoxic insults by coordinating the sensing of protein 
damage with the actions of cytoprotective response pathways and chaperone networks (23). Its 
unique hallmark is the marked induction of genes encoding heat shock proteins (HSPs) and 
chaperones, which preserve cellular protein homeostasis by counteracting protein misfolding, 
unfolding, and aggregation. The expression of these genes is driven by heat shock transcription 
factor 1 (HSF1), commonly coined the master regulator of the HSR. 
 
Despite the HS-induced modification of chromatin-associated proteins by SUMO-2/3, the global 
chromatin-binding profile of SUMO-2 during HS has not been addressed. Here, by combining 
data from chromatin immunoprecipitation assays coupled to high-throughput DNA sequencing 
(ChIP-seq) and RNA sequencing (RNA-seq) with previously published proteomics data, we 
show that in response to HS, SUMO-2 is rapidly conjugated to protein complexes associated 
with the DNA-regulatory elements of active genes that encode regulators of gene expression and 
posttranscriptional modification of RNA. Rather than acting as a direct transcriptional repressor 
or activator during HS, HS-induced SUMO conjugation appears to be an integral component of 
the proteotoxic stress response. Our data implicate SUMO conjugation as an immediate early 
mechanism required for the maintenance of protein complex homeostasis in response to protein 
damage. We suggest that, by complementing the action of HSPs, proteotoxic stress-induced 
SUMO conjugation is required to tolerate the transient accumulation of damaged and misfolded 
proteins. 
 
RESULTS 
ChIP-seq reveals substantial increases in the binding of SUMO-2 to active DNA-regulatory 
elements in response to HS 
To characterize changes in the association of SUMO-2 with chromatin in response to HS in an 
unbiased manner, we used chromatin immunoprecipitation (ChIP) coupled to high-throughput 
sequencing (ChIP-seq) to determine the genome-wide profiles of SUMO-2 in U2OS (human 
osteosarcoma) cells that were either unstressed or were subjected to HS by shifting the 
incubation temperature of the cells to 43°C for 30 min (HS cells), when global conjugation of 
proteins by SUMO-2/3 is maximal (17). SUMO-2–bound chromatin was enriched from 
crosslinked cell extracts with an antibody with previously confirmed specificity for SUMO-2 
(24). Total genomic DNA was sequenced to obtain reference input profiles (fig. S1A). We 
applied the model-based analysis of ChIP-seq (MACS) peak-calling algorithm (25, 26) to 
identify sites of statistically significantly increased SUMO-2–binding in HS cells compared to 
that in untreated cells and input control. The observations described here are based on SUMO-2–
binding sites common to two independent ChIP-seq experiments showing a very similar pattern 
of binding of SUMO-2 to chromatin before and in response to HS (fig. S1B). 
 
This analysis revealed the HS-induced recruitment of SUMO-2 to chromatin, and indicated that 
the binding of SUMO-2 to chromatin markedly changed in response to HS at 13390 sites shared 
between both replicate datasets (Fig. 1A and fig. S1C). These sites represent discrete loci that 
centered on an average core region of 500 to 1000 bp and were already marked by variable, but 
low, amounts of chromatin-bound SUMO-2 before HS was induced (Fig. 1, A and B, and fig. S1, 
C and D). In contrast, we detected only 726 sites shared between both replicate datasets that were 
depleted of SUMO-2 in response to HS, indicating that, overall, this stress caused a substantial 
increase in global SUMO-2 binding to chromatin (Fig. 1A, and fig. S1C). Unlike genomic 
regions bound by SUMO-2 in response to HS, sites depleted of SUMO-2 upon HS did not 
correlate with the number of genes and regulatory features per chromosome (fig. S2, A to D). 
Thus, our study focused on genomic loci that showed increased HS-induced binding of SUMO-
2. This SUMO-2 ChIP-seq analysis confirmed the previously reported HS-induced recruitment 
of SUMO-2 to the HSPA1A (HSP70) promoter (27), but also revealed substantial binding of 
SUMO-2 to the HSPA1A gene body and to the HSPA1B and HSPA1L genes. Statistically 
significant enrichment of SUMO-2 was also detected at numerous regions for which no HS-
induced SUMO-2 binding has been reported to date, including the CHD4, RPS16, and ZNF331 
gene loci (Fig. 1C). 
 
Under HS conditions, SUMO-2 is covalently attached to a large set of nuclear substrates that are 
enriched for transcription factors and chromatin-binding proteins (17). To relate HS-induced 
SUMO-2 ChIP-seq peaks to regulatory factor–binding sites in chromatin, the number of 
observed SUMO-2 peaks per chromosome was compared to the number of expected peaks. This 
revealed that the number of observed SUMO-2 peaks correlated with genes and regulatory sites 
in chromatin (fig. S2, A and B). Second, SUMO-2 ChIP-seq signals were compared to sites of 
transcription factor–binding and enhanced chromatin accessibility from unstressed cells 
(ENCODE, see Materials and Methods for GEO accession numbers). Regions of enhanced 
sensitivity to nucleases, such as DNaseI, correspond to nucleosome-depleted regions. These 
nuclease-hypersensitive sites mark active cis-regulatory elements, including transcription start 
sites (TSSs), enhancers, insulators, and silencers. The region of maximal nuclease sensitivity 
directly correlates with maximal regulatory factor occupancy (28). Analysis of this data (29) 
revealed the co-occurrence of SUMO-2–enriched peaks at regions of enhanced chromatin 
accessibility as defined by DNaseI-hypersensitivity, formaldehyde-assisted isolation of DNA 
regulatory elements (FAIRE), and transcription factor–binding site data (ChIP synthesis) (Fig. 1, 
D and E). This co-location of SUMO-2 peaks and DNaseI–hypersensitive sites (DHSs) was 
observed for individual sites associated with the HSPA1A, CHD4, ZNF331, and RPS16 loci (Fig. 
1C). Together, these observations imply that SUMO-2 covalently modifies substrate proteins that 
occupy active DNA-regulatory elements during HS. 
 
SUMO-2 localizes to DNA-regulatory elements predominantly associated with genes and an 
active chromatin environment 
More than two-thirds (73%) of all SUMO-2–enriched sites are located within protein-coding 
genes or their proximal regions spanning 2 kb upstream or downstream (9721 peaks, 8292 genes) 
(Fig. 2A). Whereas most (55%) SUMO-2 peaks map to the promoter-proximal region, only 1% 
localize to the 2-kb region downstream of genes. Of the remaining SUMO-2 peaks, 17% are 
located within gene bodies, and less than a third (27%) are found in the intergenic region (> 2 kb 
from any protein-coding gene), possibly representing distal gene-regulatory elements (Fig. 2A 
and fig. S3, A to G) (30, 31). 
 
In agreement with the observed HS-induced recruitment of SUMO-2 to the promoter-proximal 
region of genes, 7325 HS-induced SUMO-2 peaks map to gene start sites (± 2 kb of the gene 
start position; 6290 genes) (Fig. 2B and fig. S4) (30, 31). Concordantly, comparison of SUMO-2 
peaks with ENCODE transcription factor–binding datasets showed a strong co-occurrence of 
SUMO-2 and several transcription- and chromatin-binding factors (fig. S5, A and B). For 
example, SUMO-2 peaks corresponded to binding sites for general transcriptional regulators and 
chromatin-remodelers, including GTF2F1, TBP, and CHD2, whereas binding sites for the RNA 
polymerase III subunit POLR3A or the inflammatory response specific transcription factor 
Signal transducer and activator of transcription 3 (STAT3) did not co-locate with SUMO-2 
peaks. Comparing the co-location of transcription factor–binding sites with either all genome-
wide SUMO-2 peaks or SUMO-2 peaks found at the TSSs of protein-coding genes revealed that 
co-location was more pronounced at TSS-associated SUMO-2 peaks (fig. S5, A and B). 
Comparison of the genome-wide distribution of SUMO-2–binding sites with ChIP-seq profiles 
for several histone modifications (ENCODE) revealed that, during HS, SUMO-2 targeted a 
genomic environment that was already enriched for active histone marks, including acetylated 
Lys27 (K27) of histone H3 (H3K27ac), H3K9ac, trimethylated K4 of histone H3 (H3K4me3), 
and dimethylated K4 of histone H3 (H3K4me2), before HS was induced (Fig. 2, C to E). 
Repressive histone modifications, including H3K27me3 and H3K9me3, were excluded from 
SUMO-2–occupied regions (Fig. 2, C and D). Thus, SUMO-2 was enriched at DHSs that 
correspond to regions that were depleted of all histone marks and were flanked on either side by 
regions enriched in active histone marks. This is exemplified by the genomic landscape at the 
EIF2S2, DEDD2 and ZNF526 genes (Fig. 2E). These data suggest that HS-induced modification 
by SUMO-2 targets chromatin-regulatory factors embedded in or recruited to a chromatin 
environment that is marked by active histone modifications before HS occurs. 
 
SUMO-2 targets active genes associated with gene expression and the posttranscriptional 
modification of RNA 
To understand the biological functions of proteins encoded by SUMO-2 target genes during HS, 
we subjected our list of 8292 SUMO-2–bound protein-coding genes (gene ± 2 kb) to functional 
analysis. This demonstrated that HS-induced modification by SUMO-2 targeted an extensive set 
of actively transcribed genes. Most statistically significantly enriched were those genes that 
encode factors involved in gene expression and posttranscriptional modification of RNA (Fig. 
3A). Previous proteomics studies revealed that SUMO-2 substrates were particularly enriched for 
factors associated with biological processes almost identical to those associated with the SUMO-
2 target genes during HS (16-18). To assess this apparent similarity more directly, we compared 
our HS TAP-SUMO-2 (SUMO-2 fused to a tandem affinity protein tag) substrate dataset, which 
lists cellular targets of HS–induced SUMOylation identified by a quantitative proteomics 
approach (17), with our ChIP-seq dataset of genes that were bound by SUMO-2 in response to 
HS. This comparative analysis showed that the two most statistically significantly enriched 
biological processes shared by both datasets are “gene expression” and “RNA posttranscriptional 
modification” (Fig. 3A). Indeed, of the individual HS-induced SUMO-2 substrates identified by 
proteomics, 70% of the genes encoding these proteins were marked by SUMO-2 modification 
after HS, suggesting that SUMO-2 conjugation modulated gene expression and RNA-
modification pathways at multiple levels during HS (Fig. 3B). 
 
SUMO-2 is required to maintain expression of its target genes  
To assess the effect on gene expression of the binding of SUMO-2 to active DNA-regulatory 
elements, we used RNA-seq to measure mRNA abundance in cells before HS was induced or 4 
hours afterwards. This analysis showed that genes associated with HS-induced SUMO-2 peaks 
were generally more highly expressed than were genes that did not recruit SUMO-2 (hereafter 
referred to as non-SUMO-2 target genes) (Fig. 3C). To address whether the recruitment of 
SUMO-2 to active promoters was involved in their transcriptional repression or activation during 
HS, we performed differential expression analysis between SUMO-2 target genes and non-
SUMO-2 target genes (Fig. 3D). This analysis revealed that, similar to non-SUMO-2 target 
genes, SUMO-2 target genes could be categorized into groups of genes that were induced or 
repressed, or whose mRNA abundance was not altered during HS. To characterize the regulation 
and function of SUMO-2–bound genes, genes with a False Discovery Rate (FDR) ≤ 0.01 were 
grouped according to their differential expression and SUMO-2 binding status in response to HS. 
The top 25% of genes in each category, as judged by fold-change in gene expression after HS, 
were then subjected to functional analysis (Fig. 3E). This revealed that HS-repressed SUMO-2 
target genes were linked with biological processes, including “gene expression” and “cell cycle,” 
whereas HS-induced SUMO-2 target genes were particularly associated with terms such as “cell 
death and survival” and “cellular growth and proliferation.” Accordingly, SUMO-2 target genes 
include many that encode stress-inducible regulators of cell death and survival, as well as 
chaperones, and they share HSF1 as a common upstream regulator (Fig. 3F and fig. S6, A to D 
and fig. S7A). These data suggest that HS-induced modification by SUMO-2 preferentially 
targets either genes that are highly active in unstressed cells or those whose expression is 
induced upon HS. These findings also imply that the recruitment of SUMO-2 to active DNA-
regulatory elements does not determine whether an associated gene is activated or repressed 
during HS. 
 
To test the role of SUMO conjugation on gene expression during HS, the expression of UBC9, 
which encodes the SUMO-conjugating enzyme UBC9, was inhibited by short inhibitory RNA 
(siRNA), and newly synthesized mRNA was measured in unstressed cells and in cells subjected 
to HS for 30 min or 1 or 2 hours. Based on our ChIP-seq and RNA-seq data, we compared 
SUMO-2–bound genes with non-SUMO-2–bound genes. Quantification of 4-thiouridine–
labelled newly synthesized RNA showed that UBC9 was required for the active expression of a 
number of SUMO-2–bound genes in unstressed cells (Fig. 3F and fig. S7A). Abrogation of HS-
induced SUMO-2 conjugation led to a reduction in the expression of many SUMO-2 target 
genes, including DDX28 and the HS-inducible CRYAB and HspA1A genes (Fig. 3F and fig. 
S7A). In contrast, expression of most of the tested HS-induced non-SUMO-2 target genes, 
including HLA-G, MAGEB4, and EPGN, was generally not impaired, but rather increased in the 
absence of SUMO conjugation (Fig. 3G and fig. S7B). 
 
Because HSF1 can be SUMOylated, it was important to exclude the possibility that impaired 
HSF1 activation accounted for the reduced expression of SUMO-2 target genes in UBC9-
depleted cells. However, neither the HSF1 protein amount nor its HS-induced activation, as 
measured by Western blotting analysis of its phosphorylation on Ser326 (32) and the appearance 
of a high molecular mass species of HSF1, were substantially affected by depletion of UBC9 
(fig. S7C). Furthermore, impaired SUMOylation of HSF1 would be expected to result in 
increased transcriptional activity of HSF1, rather than having an inhibitory effect (33). These 
results suggest that SUMO conjugation is required to maintain the maximal expression of 
SUMO-2 target genes during HS by regulating the maintenance of gene-associated transcription-
regulatory protein complexes. 
 
The pattern of HS-induced SUMO-2 conjugation on chromatin suggests that SUMO is an 
integral component of the proteotoxic stress response 
Because the HS-induced conjugation of SUMO-2 to proteins did not appear to act as a direct 
transcriptional repressor or activator of target genes, we investigated the possibility that SUMO-
2 conjugation is an integral component of the HSR that regulates protein homeostasis of 
chromatin-associated regulatory complexes. A direct link between SUMO-2 conjugation and the 
HSR is supported by the observation that SUMOylation represents an immediate event after an 
increase in temperature (17, 20). Accordingly, when we characterized the dynamics of the 
recruitment of SUMO-2 to chromatin, we noted that SUMO-2 occupancy at DHSs in response to 
HS mirrored the temporal pattern of global SUMO-2 conjugation in cells (Fig. 4, A and B). 
Within 5 min of HS induction, SUMO-2 and SUMO-1 were enriched at all of the DHSs that 
were examined (Fig. 4B). After reaching a maximal occupancy after approximately 30 of HS, the 
amounts of chromatin-bound SUMO-2 and SUMO-1 began to decrease (Fig. 4B). Despite a 
uniform pattern of SUMO recruitment across DHSs, the clearance of SUMO from the HSPA1A 
promoter appeared to follow faster kinetics than were observed for other loci (Fig. 4B). We 
suggest that this difference is based on faster recycling rates of transcription regulatory protein 
complexes linked to high transcriptional activity at the HSPA1A locus. Overall, these 
observations support the idea that the SUMO modification status during HS is controlled by a 
central mechanism that acts on a system-wide scale and is interlinked with the HSR. ChIP 
experiments with an antibody raised against PIAS1 (fig. S8, A and B) revealed that the kinetics 
of the HS-induced recruitment to chromatin of the SUMO E3 ligase PIAS1 was similar to that of 
SUMO (fig. S8C), suggesting that at least a fraction of SUMO modification occurs directly on 
chromatin. Whereas single depletion of individual PIAS proteins (PIAS1 to PIAS4) did not result 
in a major reduction in the amount of SUMO-2 at DHSs, simultaneous ablation of all four PIAS 
isoforms abolished the recruitment of SUMO-2 to DHSs (Fig. 4C). 
 
To investigate the temporal dynamics of HS-induced SUMOylation, we compared the 
recruitment of SUMO to DHSs both in response to HS and after a 2-hour recovery period at 
37°C. After recovery from HS, the amounts of chromatin-associated SUMO-2 and SUMO-1 
were reduced to those before treatment; however, exposure of cells to a second round of HS after 
a recovery period of 2, 8, or 12 hours led to impaired recruitment of SUMO-2 and SUMO-1 (Fig. 
5A and fig. S9A). To establish the cellular compartments that provided the pool of free SUMO-2 
that was used for HS-induced conjugation, cells were subjected to HS and recovery as described 
earlier, but before analysis, the cells were fractionated into cytoplasmic and nuclear extracts (Fig. 
5B). An inverse relationship was observed between the pattern of binding of SUMO-2 to 
chromatin (Fig. 5A and fig. S9A) and the cytoplasmic pool of monomeric SUMO-2, which was 
rapidly depleted because SUMO-2 was conjugated to nuclear substrates during HS (Fig. 5B). 
After a 2-hour recovery period, when the amounts of nuclear proteins conjugated with SUMO-2 
declined, the cytoplasmic pool of monomeric SUMO-2 was restored (Fig. 5B).  
 
In response to HS, HSF1 is released from HSP70- and HSP90-mediated inhibition in the 
cytoplasm and translocates to the nucleus to drive the expression of HSP-encoding genes, 
including HSPA1A (34, 35). When the extent of SUMO-2 conjugation was maximal after 30 min 
of HS, the amounts of HSP70 protein remained similar to those in unstimulated cells (Fig. 5B). 
However, after a 2- or 8-hour recovery period from HS, when SUMO-2–conjugated proteins had 
declined to background amounts, an increase in the amount of HSP70 protein was apparent (Fig. 
5B and fig. S9B). Consistently, SUMO-2 conjugation was fully restored only after a recovery 
period of 24 hours, which resulted in a concomitant decrease in the cellular amounts of HSP70 
(fig. S9B). 
 
An alternative approach to investigating the link between the HSR and SUMO conjugation was 
provided by pharmacological inhibition of the chaperone function of HSP90. Cells were treated 
with two structurally distinct HSP90 inhibitors, 17-AAG or CCT018159 (36, 37). Both inhibitors 
relieved the block on SUMO-2 conjugation caused by the initial round of HS and substantially 
restored the amounts of nuclear SUMO-conjugates that were attained during the second round of 
HS (Fig. 5B). To reveal whether this effect was HS-specific or represented a general regulatory 
mechanism of proteotoxic stress–induced SUMO conjugation, proteotoxic stress was induced by 
treating the cells with MG132, which disrupts cellular protein homeostasis by blocking the 
proteasomal degradation of incorrectly folded proteins. Similar to the effects of HS, MG132 
caused an increase in the conjugation of SUMO-2 to nuclear substrates (Fig. 5C), and, with the 
exception of the HSPA1A promoter, led to substantial recruitment of SUMO-2 to the same 
genomic loci that were targeted by SUMO-2 during HS (Fig. 5D and fig. S9C). The lack of 
robust SUMO-2 occupancy at the HSPA1A promoter correlated with weak activation of HSF1 in 
response to MG132 as judged by the translocation of HSF1 to the nucleus and the impaired 
mobility of the protein in an SDS-PAGE gel (Fig. 5, B and C). Additionally, MG132-induced 
SUMO-2 conjugation was inhibited by a preceding round of HS. As was observed for HS, this 
block in MG132-induced SUMO-2 conjugation was relieved by pharmacological inhibition of 
HSP90 (Fig. 5C). Furthermore, L-canavanine, a non-proteinogenic L-arginine analog that 
disrupts protein structure upon its incorporation, also led to the recruitment of SUMO-2 to 
chromatin (Fig. 5E and fig. S9D). When comparing the dynamics of HSF1 nucleo-cytoplasmic 
translocation, and thus HSF1 activation, with those of SUMO-2 conjugation in response to HS 
and MG132, we noted that the temporal and subcellular activation pattern of HSF1 correlated 
with that of SUMO-2 conjugation (Fig. 5, B and C), suggesting that SUMO-2 conjugation also 
forms an integral component of the HSR and is regulated as such. 
 
Consistent with the observation that the recruitment of SUMO-2 to chromatin was impaired in 
response to a second round of HS (Fig. 5A and fig. S9A), SUMO-2 remained almost entirely in 
its cytoplasmic, monomeric form, suggesting that SUMO was rapidly deconjugated from its 
substrates upon removal of the stress stimulus, and that further conjugation was inhibited (Fig. 
5B). Concordantly, the SUMO protease SENP6 was also recruited to active DNA-regulatory 
elements upon HS (Fig. 6, A to E). 
SUMO-2 targets large protein complexes during HS 
Because SUMO-2 conjugation appeared to form a central part of the proteotoxic stress response, 
it seemed reasonable to suggest that SUMO itself might maintain the integrity of the regulatory 
complexes that occupied active DNA-regulatory elements. To test this hypothesis, we used ChIP 
analysis to assess the HS-induced recruitment of SUMO-2 to DNA-regulatory elements in cells 
individually depleted of SUMO-2 substrates likely to localize to TSSs (17), such as HSF1 and 
the E3 ubiquitin-protein ligase ubiquitin-like PHD and RING finger domain–containing protein 1 
(UHRF1). To study the recruitment to chromatin of UHRF1, we raised an antibody against this 
protein and validated its specificity (fig. S10, A and B). Both HSF1 and UHRF1 are known 
SUMO-2 substrates and are specifically localized to active DNA regulatory elements of the 
CHD4 promoter, but not to a control site 1800 bp upstream, upon exposure to HS (fig. S10, C to 
F) (17). Whereas depletion of HSF1 led to the reduced binding of HSF1 to the promotors of 
CHD4, ZNF331, and RPS16 (fig. S10, C, G, and H), the recruitment of SUMO-2 was not 
affected during HS (fig. S10, I to K). Similarly, the amounts of SUMO-2 at the CHD4 promoter 
were unaltered in cells depleted of UHRF1, although the amounts of UHRF1 were reduced (fig. 
S10, B and L). These data suggest that the pool of SUMO-2 recruited to DHSs upon HS was not 
the result of one single factor being SUMOylated at these sites or of one single SUMO-2–
modified protein being recruited. Instead, the data suggest that SUMO-2 recruitment was a 
combination of the HS-induced modification by SUMO-2 of multiple substrates, for example 
components of multiprotein complexes. During HS, most cellular substrates of SUMO associated 
with the insoluble, nuclear fraction (fig. S11A). SUMOlyated proteins were released from this 
fraction by increasing the salt concentration, suggesting that SUMO was associated with large 
protein complexes upon HS (38). Salt-induced release of SUMO conjugates from this insoluble 
material required pretreatment with benzonase or DNaseI, suggesting that the SUMOylated 
protein complexes were tightly associated with DNA and chromatin (fig. S11, A and B). 
 
DISCUSSION 
SUMO conjugation is implicated as an important stress response mechanism (15-17, 19, 20). 
Here, we showed that SUMO conjugation acts as a dynamic and integral component of the HSR. 
Upon HS, both SUMO-2 and SUMO-1 were conjugated to components of large nuclear protein 
complexes that are involved in the regulation of active gene expression and posttranscriptional 
modification of RNA in either proliferating cells or during HS. Integration of our ChIP-seq and 
RNA-seq datasets revealed that a substantial proportion of these SUMO-modified complexes 
was associated with transcription factor–binding sites located close to the TSS of many highly 
expressed genes. These DNA regulatory elements were nucleosome-depleted and are flanked on 
either side by stretches of active histone marks, implying that chromatin-binding factors, rather 
than histones, were the targets for SUMO modification. Other forms of protein-damaging stimuli 
induced a similar recruitment of SUMO to chromatin, implying that SUMO conjugation is not 
HS-specific, but is a general response to proteotoxic stress. 
 
In concurrence with a study describing the dynamic enrichment of SUMO at predominantly 
active genes in WI38 human fibroblasts grown under normal conditions, our data reveal that HS-
induced SUMO-2 target genes were also enriched for fundamental cellular processes such as 
gene expression and cell cycle (39). However, whereas the SUMO pathway has a predominantly 
repressive function on the transcription of many genes that encode factors that regulate growth 
and proliferation in fibroblasts, our data suggest that SUMO is required for maximal expression 
of many of its target genes during HS. In particular, the association of SUMO-2 with HS-induced 
genes encoding survival factors offers a mechanism by which SUMO contributes to increased 
survival rates of cells after proteotoxic stress. 
 
Our work reveals SUMO conjugation as an integral component of the HSR and proteotoxic 
stress response, and suggests a model in which HS-induced SUMO conjugation targets large, 
chromatin-associated protein complexes to maintain their homeostasis during proteotoxic stress. 
Evidence in support of this model is based on three observations. First, our data suggest a direct 
link between SUMO conjugation and the HSR. The almost identical set of activating stimuli (15, 
16, 20, 40, 41) and the fact that the dynamics of proteotoxic stress–induced SUMO conjugation 
resemble those of HSF1 activation imply that both pathways shared a common upstream 
regulatory mechanism. Similar to HSF1 activation, proteotoxic stress-induced SUMO 
conjugation and recruitment of SUMO to chromatin were impaired in cells preconditioned by a 
priming HS, suggesting that this initial HS induced a common inhibitor of both pathways. In 
addition to our finding that the priming HS event led to increased amounts of HSP70 protein, 
which negatively correlated with SUMO conjugation, overexpression of HSP70 in plants results 
in a block in HS-induced SUMOylation (20). Further reinforced by the observation that 
pharmacological inhibition of a different chaperone, HSP90, restored proteotoxic stress–induced 
SUMO conjugation in cells that had been preconditioned by a priming HS, we propose a model 
in which proteotoxic stress–induced SUMOylation is dependent on HSP70 and HSP90. The pool 
of monomeric SUMO-2 is likely to be located in the cytoplasm in unstressed cells because 
cellular fractionation experiments showed a predominantly cytoplasmic localization of 
unconjugated SUMO-2. This observation is unlikely to be the consequence of monomeric 
SUMO-2 leaking out of the nucleus during the fractionation procedure, because this would result 
in the free SUMO being evenly distributed between nuclear and cytoplasmic compartments. In 
analogy to the “chaperone titration model” that was suggested for HSF1 regulation (42), we thus 
suggest that SUMO-2 is also negatively controlled by a repressive, cytoplasmic heteroprotein 
complex consisting of the HSP70 and HSP90 chaperones. Proteotoxic stress–induced 
accumulation of misfolded proteins stimulates the release of SUMO-2 and HSF1 from this 
inhibitory complex while these chaperones are redirected towards sites of protein damage. 
However, excessive amounts of HSP present in response to an initial HS event would lead to a 
block in SUMO conjugation and HSF1 activation upon a second proteotoxic stress stimulus. 
Therefore, conjugation of SUMO-2 to nuclear substrates appears to require two separate events: 
release from HSP70- and HSP90-dependent cytoplasmic retention and the accumulation of 
unfolded proteins in the nucleus as an additional trigger. 
 
Second, numerous observations have implicated SUMO in the maintenance of protein complex 
stability under conditions of compromised protein homeostasis. Several studies focusing on the 
identification of SUMO substrates in yeast and human cells demonstrated that the SUMO 
pathway preferentially targets components of macromolecular protein complexes for 
modification (16, 17, 43-46). This function of SUMO is required in various biological pathways, 
including DNA damage repair (45), ribosome assembly (47, 48), and the establishment of protein 
complexes required for dosage compensation, the epigenetic process responsible for the 
normalization of gene expression that results from unequal copy numbers of sex chromosomes, 
in C. elegans (49). Proteotoxic stress-induced SUMO substrates are enriched for a diverse set of 
transcription factors and chromatin remodelers (16-18, 46). These factors are typical components 
of the large protein complexes commonly associated with active DNA-regulatory elements that 
are also sites of HS-induced SUMO recruitment. Stabilization of pre-existing, chromatin-bound 
regulatory complexes, at TSSs for example, during proteotoxic stress is crucial, because their 
deposition and replacement is often confined to a narrow window of the cell cycle, such as on-
going DNA replication during S-phase (50, 51). Thus, we propose that the SUMO-mediated 
maintenance of protein complex homeostasis is essential for maintaining the regulatory status 
quo of gene promoters and other SUMO-associated DNA-regulatory elements. This role of 
SUMO in protein complex stability is exemplified by the requirement for SUMO modification in 
Promyelocytic leukemia protein (PML) nuclear body formation (52). We propose that SUMO 
modulates protein complex homeostasis by exhibiting chaperone-like functions. There are 
several mechanisms that SUMO might use to achieve these functions. Comparable to the 
stabilizing effect of HS-induced, PARP-dependent ADP-ribose polymers on the HSP70 locus 
(53), SUMO could exert a stabilizing effect on protein assemblies and act as a scaffold or glue by 
potentiating physical interactions between protein complex components (45). For example, one 
SUMO-modified protein can interact with another non-SUMOylated protein through just 
SUMO-SIM interactions. According to this model, the scaffolding effect of SUMOylation would 
not be restricted to covalently modified SUMO substrates or proteins already in direct contact 
with each other, but would also support indirect interactions between distant complex 
components, an effect that could even be potentiated by simultaneous modification of some 
proteins at multiple sites (46). Consequently, only a small number of proteins within a complex 
need to be SUMOylated under these circumstances. Additionally, the SUMO scaffold can be 
rapidly disassembled through the action of SUMO-specific proteases, for example, to enable 
protein complexes to resume their normal functions in cells recovering from a protein-damaging 
insult. Similar to the function suggested for polyphosphate chains (54), HS-induced poly-SUMO 
chain formation (17, 21) could also be required for the maintenance of protein solubility, thereby 
antagonizing the irreversible aggregation of complex components and promoting the 
maintenance of a refolding-competent state. This proposal is supported by a study that described 
the N-terminal tail of SUMO as an entropic bristle whose disordered structure exerts a 
solubilizing effect on associated or modified proteins by increasing their soluble surface areas 
and limiting contacts between aggregation-prone protein folds (55). Therefore, as an acute and 
reversible protein modification, SUMO conjugation would be a powerful mechanism to prevent 
protein aggregation and would enable adaptation to stress without the requirement for de novo 
RNA or protein synthesis. Finally, further evidence supporting a direct involvement of SUMO in 
the proteotoxic stress response is contributed by studies in plants and cultured human cells, 
which demonstrated a requirement for SUMO for cell survival in response to hyperthermic stress 
(17, 19). 
 
MATERIALS AND METHODS 
Cell culture and treatments 
U2OS cells were cultured according to standard procedures. To induce HS, cells were incubated 
at 43°C for the times indicated in the legends. To induce proteotoxic stress through the 
incorporation of L-canavanine, cells were cultured for 12 hours in Dulbecco’s Modified Eagle 
Medium (DMEM) in which L-arginine was replaced with L-canavanine. To inhibit proteasomes, 
cells were incubated in the presence of 50 μM MG132 for the times indicated in the legends. To 
inhibit HSP90, cells were incubated with 1 μM 17-AAG [17-(Allylamino)-17-
demethoxygeldanamycin) or 10 μM CCT018159 as indicated. DMSO was used as vehicle 
control. 
 
Cell lysis and fractionation 
To generate whole-cell lysates, cells were lysed directly in 2 x Laemmli sample buffer. To 
fractionate cells into cytoplasmic and nuclear lysates, 0.5 to 1 x 107 U2OS cells were washed in 
phosphate-buffered saline (PBS) and scraped into ice-cold PBS containing 100 mM 
iodoacetamide. Cell pellets were resuspended in approximately 300 µl of ice-cold buffer A [10 
mM Hepes (pH 7.8), 0.08% NP-40, 10 mM KCl, 1.5 mM MgCl2, protease inhibitors, 100 mM 
iodoacetamide]. All buffers were supplemented with RNasin (20 U/ml, Promega) when nuclei 
were prepared for treatment with DNaseI. After incubation on ice for 15 min, cells were gently 
syringed 20 times through a 19G needle, and nuclei were separated from the cytoplasmic fraction 
by centrifugation at 500 g. Nuclei were washed twice in buffer A without iodoacetamide before 
lysis in SDS lysis buffer. Equal amounts of lysates were resolved by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) and analyzed by Western blotting. To separate nuclear contents 
into soluble, chromatin-associated, and insoluble, “matrix-associated” fractions, nuclei were 
treated with benzonase (125 to 250 U/ml for 1 to 3 x 106 nuclei, Fermentas) or DNaseI (500 
U/ml for 1 to 3 x 106 nuclei, Roche) for 1 hour at 4°C or room temperature, respectively. For 
salt-extraction of nuclear material, benzonase- or DNaseI-treated nuclei were incubated for 3 min 
with 0.3 or 0.5 M NaCl, respectively. Soluble and insoluble fractions were separated by 
centrifugation at 17,000g for 5 min at 4°C. 
 
siRNA 
siRNA was purchased from Dharmacon. Cells were transfected with siRNAs according to 
established protocols for Lipofectamine RNAiMAX (Invitrogen). 
 
Metabolic labelling, purification, and quantitation of newly synthesized RNA 
Metabolic labelling, biotinylation, and purification of newly synthesized RNA were performed 
as described previously (56) with the following modifications. U2OS cells were transfected with 
non-targeting siRNA or UBC9-specific siRNA and incubated for 96 hours. For metabolic 
labelling of RNA for a one-hour, single time point (fig. S7, A and B), U2OS cells were left 
untreated or were subjected to HS at 43°C for 5 min. 4-thiouridine (500 μM, 4SU, Sigma) was 
added directly to the tissue culture medium and the cells were incubated at 37°C or 43°C for a 
further 55 min. Total cellular RNA was isolated with the RNeasy Mini kit (Qiagen). 
Biotinylation of 4SU-labeled RNA was performed by incubating 80 to 100 μg of total RNA at a 
final concentration of 100 ng/μl in a buffer containing EZ-Link HPDP-Biotin [N-[6-
(Biotinamido)hexyl]-3'-(2'-pyridyldithio)propionamide, 0.2 mg/ml, Thermo], 10 mM Tris (pH 
7.4), and 1 mM EDTA for 90 min at room temperature. Unbound HPDP-Biotin was removed by 
two rounds of extraction with chloroform:isoamylalcohol (24:1, Sigma) in Phase-lock-gel 
(heavy) tubes (Eppendorf). RNA was precipitated by the addition of a 1/10 volume of 5 M NaCl 
and an equal volume of isopropanol, followed by centrifugation at 20,000g for 20 min. After two 
washes with 75% ethanol, the RNA pellet was resuspended in RNase-free water, denatured by 
incubation at 65°C for 10 min, and cooled on ice. Biotinylated RNA was captured with 
Dynabeads MyOne Streptavidin C1 (Invitrogen) that were prepared according to the 
manufacturer’s instructions. For RNA capture, RNA was incubated with an equivalent of 100 µl 
bead solution in a buffer containing 5 mM Tris (pH 7.4), 0.5 mM EDTA, and 1 M NaCl for 15 
min by rotation at room temperature. Bead-RNA complexes were washed three times with 1 ml 
of wash buffer [10 mM Tris (pH 7.4), 10 mM EDTA, 1 M NaCl, 0.1% Tween20] at 65°C, 
followed by three washes with wash buffer at room temperature. Newly synthesized RNA was 
eluted twice by incubation with 100 μl of 100 mM DTT for 5 min, and recovered with the 
RNeasy MinElute Spin kit (Qiagen). The concentration of purified RNA was measured with a 
Nanodrop spectrophotometer. Equal amounts of labelled RNA were reverse-transcribed into 
complementary DNA (cDNA) with qScript cDNA mastermix (Quanta). The abundances of the 
cDNAs of interest were measured by RT-qPCR analysis with gene-specific primer sets and 
taking into consideration the dilution factor derived from the adjustment of the RNA 
concentration for reverse transcription. For time-course experiments (Fig. 3, F and G), cells were 
exposed to HS for 5, 30, or 90 min before being incubated in the presence of 4-thiouridine for an 
additional 30 min at 43°C to obtain HS time points of 30, 60, and 120 min, respectively. 
 
Antibodies 
The antibodies used in this study are listed in table S1. Antigen affinity-purified sheep anti-
SUMO-1, sheep anti-SUMO-2 and sheep anti-SENP6 antibodies have been described previously 
(6, 57). Antibodies against mouse PIAS1 and human UHRF1 were raised in sheep against 
bacterially produced recombinant proteins. Antibodies were antigen affinity purified and used in 
ChIP experiments described in figures S8C and S10, B, E and F, respectively. To validate the 
antibodies, PIAS1 and UHRF1 expression was ablated by a pool of siRNA (Dharmacon) and 
extracts from these cells were compared to control cells by Western blotting (fig. S8A and fig. 
S10A) and ChIP analysis (fig. S8B and fig. S10B).  
 
ChIP 
ChIP assays were performed according to the Upstate protocol (17-295) with the following 
modifications. Approximately 1 to 2 × 106 U2OS cells were used per reaction, crosslinked by 
adding formaldehyde directly to the cell culture medium to a final concentration of 1%, and 
incubated at room temperature for 10 min. Formaldehyde was quenched by the addition of 0.125 
M glycine for 5 min. DNA was sheared to fragments of approximately 200 to 500 bp by 
sonication for 15 cycles (7.5 min total sonication time) at the high setting at 4°C with a Bioruptor 
(Diagenode). Cleared lysates were diluted 10-fold in dilution buffer [1% Triton X-100, 2 mM 
EDTA, 150 mM NaCl, 20 mM Tris (pH 8.1)]. Immunoprecipitation was performed by overnight 
incubation with 1 μg of specific antibody or control immunoglobulin G (IgG), followed by 
incubation with protein G Dynabeads (Life Technologies) for 1 hour. Eluates were incubated 
with RNase A (0.1 mg/ml, Fermentas) for 30 min at 37°C before removal of crosslinks by 
overnight incubation at 65°C in the presence of 0.2 M sodium chloride, followed by digestion 
with proteinase K (0.25 mg/ml, Roche) for 1 hour at 55°C. DNA was purified with a polymerase 
chain reaction (PCR) purification kit (Qiagen). Enrichment of chromatin-binding factors was 
assessed by real-time, quantitative PCR (RTqPCR on an ABI7500 real-time PCR machine with 
the specific primers listed in table S2. 
 
ChIP-seq 
Two independent SUMO-2 enrichment ChIP-seq data sets were generated. The first set using 
protein G sepharose 4B (Sigma; dataset 1) included untreated and HS samples for which SUMO-
2 ChIP and input (whole-cell lysates) samples were run. The second set using protein G 
Dynabeads (Life Technologies; dataset 2) consisted of untreated and HS SUMO-2 ChIP samples 
only. ChIP assays were performed as described above with the following adjustments. 
Approximately 3.5 to 4.5 × 107 U2OS cells were used per treatment. Crosslinked cell pellets 
were flash-frozen in liquid nitrogen and stored at -80°C. For the experiment with protein G 
sepharose 4B beads, frozen cell pellets were lysed in 2.1 ml of lysis buffer. DNA was sheared by 
sonication of 300-μl volumes for 14 cycles (7.5 min total sonication time) at the high setting at 
4°C with a Bioruptor (Diagenode). To capture protein-DNA complexes, a fraction corresponding 
to 90% of the cleared and diluted lysates was incubated overnight with 21 µg of anti–SUMO-2 
antibody (Life Technologies, 51-9100) and subsequently with bovine serum albumin (BSA)-
blocked protein G sepharose 4B beads (Sigma) for 1 hour with a final bead bed volume of 150 
µl. Bead-bound, protein-DNA complexes were washed twice in 14 ml of each wash buffer and 
14 ml of TE buffer and eluted into 2.5 ml of elution buffer. An equal volume of TE buffer was 
added to the eluates before incubation with RNase A (0.2 mg/ml, Fermentas) at 37°C for 2 hours. 
Samples were incubated overnight at 65°C in the presence of 0.2 M sodium chloride, followed 
by digestion with proteinase K (0.25 mg/ml, Roche) for 1 hour at 55°C. DNA was purified with 
a PCR purification kit (Qiagen). To derive genomic DNA to be used as an input reference for 
SUMO-2 ChIP-seq, a fraction corresponding to the sonicated, diluted, and cleared whole-cell 
extracts that had been prepared for SUMO-2 ChIP was removed. These input samples were 
treated to remove RNA and reverse crosslinking, and DNA was extracted as described earlier. 
When protein G Dynabeads were used, frozen cell pellets were lysed in 1.8 ml of lysis buffer. 
After sonication for 15 cycles (7.5 min total sonication time), lysates were incubated with 13 µg 
of anti–SUMO-2 antibody and subsequently with protein G Dynabeads (Life Technologies) for 1 
hour with an equivalent of 300 µl of bead solution. Bead-bound protein-DNA complexes were 
washed in 13 ml of each wash buffer and 13 ml of TE buffer and eluted into 2.3 ml of elution 
buffer. Salmon sperm DNA was not used at any stage throughout the entire protocol. 
 
ChIP-seq library construction and next generation sequencing 
Library construction and sequencing were performed at Genotypic (Bangalore, India). Libraries 
were constructed with ~10 ng of purified DNA according to a modification of the Illumina ChIP-
Seq library protocol. Briefly, DNA was subjected to end-repair and adaptor ligation (Illumina 
ChIP Seq Library preparation kit). Adapter-ligated fragments were enriched by PCR 
amplification, and libraries were size-selected by 2% low-melting agarose gel electrophoresis 
with subsequent gel purification with the MinElute gel extraction kit (Qiagen). To validate the 
quantity and quality of the libraries, aliquots were analyzed on a Nanodrop spectrophotometer 
and High Sensitivity Bioanalyzer ChIP (Agilent), respectively. Libraries were sequenced on an 
Illumina Genome Analyser IIx with either 54-bp (for experiments with protein G sepharose 4B) 
or 36-bp single-end (for experiments with protein G Dynabeads) sequencing. 
 
Sequence alignment and peak assignment 
Sequence alignment was performed with the Subread aligner included in the R-bioconductor (58) 
package Rsubread (59) against the GRCh37 human reference obtained from Ensemble. Regions 
of SUMO-2 enrichment and depletion were identified with MACS2 software (25, 26) with an 
FDR cut-off of 0.01. To combine the datasets and derive a set of high-confidence enriched and 
depleted peaks, the following procedure was followed. SUMO-2 ChIP samples where run against 
the corresponding input sample to detect SUMO-2–enriched regions, regions assigned as 
enriched for SUMO-2 in the HS samples, but not in the untreated samples, were termed “SUMO-
2–enriched peaks,” and regions assigned as enriched in the untreated, but not in the HS samples, 
were termed “SUMO-2–depleted peaks.” Regions assigned as “enriched peaks” in both 
independent datasets were termed “high-confidence enriched peaks” and similarly, regions 
assigned as “depleted peaks” in both datasets were termed “high-confidence depleted peaks. 
These high-confidence regions were further validated with MACS2 to call enriched and depleted 
regions between the HS SUMO ChIP and the untreated SUMO ChIP datasets with its model-free 
setting. These two sets of high-confidence peaks were used for subsequent analysis. 
 
Genomic features 
Datasets for the ChIP-seq of histone modifications, DNaseI-seq, and FAIRE-seq were retrieved 
from ENCODE (https://genome.ucsc.edu/ENCODE/) and are associated with the following GEO 
accession numbers: H3K4me2 (Hela-S3, GSM733734), H3K4me3 (Hela-S3, GSM733682), 
H3K9ac (Hela-S3, GSM733756), H3K27ac (HeLa-S3, GSM733684), H3K27me3 (Hela-S3, 
GSM733696), H3K79me2 (Hela-S3, GSM733669), H3K36me3 (Hela-S3, GSM733711), 
H4K20me1 (Hela-S3, GSM733689), H3K9me3  (U2OS, GSM788078), DNaseI HeLa-S3 
(GSM816643), DNaseI IMR90 (GSM468792), DNaseI Osteoblast (GSM816654), DNaseI 
LNCaP (GSM816637), FAIRE-seq (Hela-S3, GSM864348), and ChIP synthesis (Hela-S3, 
GSM1002653). Data tracks were loaded and displayed in the Integrated Genome Browser 
(http://bioviz.org/igb/). Co-occurance of SUMO-2 peaks with gene transcript annotations and 
annotated genomic regulatory features was performed with the R-bioconductor package 
ChIPpeakAnno (60) based on the coordinates of Ensembl hg19 transcripts and regulatory 
features. We assigned peaks to annotations with the following hierarchy: 2 kb upstream of the 
TSS > first exon > other exon > first intron > other intron > 2 kb downstream of the transcript 
end > intergenic (> 2 kb from any transcript). To analyze the statistical significance of the co-
occurance of SUMO-2 peaks and histone marks, open chromatin, or transcription factor–binding 
sites, we compared our SUMO-2 ChIPseq data to respective datasets obtained from ENCODE 
(61) using IntervalStats (29). IntervalStats generates an exact P value that represents the 
probability that the query feature (the SUMO-2 peak) would be as closely or more closely 
associated with the reference feature (for example, a DHS) within the specified region of interest 
(for example, a 4-kb window surrounding a TSS) if its location was selected by random chance. 
This is calculated by dividing the number of places as close or closer to the reference feature by 
the number of all possible locations. In contrast to a classical P value, it is an exact P value, 
because all possible locations are calculated rather than applying a subsampling approach of an 
assumed statistical distribution. An exact P value is generated for each query feature against all 
target features in each domain, and a distribution of exact P values is generated describing the 
co-occurance of the feature rather than a single P value. 
 
RNA-seq 
U2OS cells were left untreated or subjected to heat shock at 43°C for 4 hours. Extraction of total 
RNA from three replicate samples was performed with the RNeasy mini kit (Qiagen) according 
to the manufacturer’s instructions. Library preparation and transcriptome sequencing were 
performed at the Beijing Genomics Institute (BGI). Briefly, to generate a sequencing library 
suitable for transcriptome analysis, mRNA was purified, fragmented, and reverse-transcribed 
into cDNA according to the Illumina protocol. The resulting cDNAs were then ligated to 
adapters, PCR-amplified, size-selected (200-bp), and validated with a 2100 Bioanalyser 
(Agilent) and an ABI StepOnePlus Real-Time PCR System. Libraries were subjected to 91-bp, 
paired-end sequencing on a HiSeq2000 instrument (Illumina). Sequence alignment was 
performed using tophat2 (62) against the GRCh37 human reference from Ensembl. Reads were 
assigned to transcripts with featureCounts from the Rsubread software package (59), and 
differential expression analysis was performed with the R-bioconductor package DESeq (63). 
 
Gene ontology analysis  
Comparative analysis and analysis of the biological functions of genes and proteins was 
performed with IPA Ingenuity software. 
 
SUPPLEMENTARY MATERIALS 
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Fig. S2. Correlation of SUMO-2 peaks with features and genes. 
Fig. S3. Examples of SUMO-2 peaks associated with different genomic annotations. 
Fig. S4. Alignment of HS-induced SUMO-2 peaks with the TSSs of protein-coding genes. 
Fig. S5. Co-occurrence of HS-induced SUMO-2 peaks and binding sites of selected transcription 
factors and chromatin-binding factors. 
Fig. S6. Upstream regulatory pathway analysis for SUMO-2 target genes and genes not bound by 
SUMO-2. 
Fig. S7. Effect of siRNA-mediated depletion of UBC9 on gene expression. 
Fig. S8. Kinetics of the HS-induced recruitment of PIAS1 and SUMO-2 to chromatin. 
Fig. S9. The HS-induced recruitment of SUMO to chromatin is part of the proteotoxic stress 
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Fig. S10. Relationship between HS-induced SUMO occupancy and the recruitment of HSF1 and 
UHRF1 to chromatin. 
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Fig. 1. Genome-wide analysis of SUMO-2 chromatin occupancy during HS. (A) SUMO-2 
occupancy at enriched, depleted, and control sites in untreated U2OS cells and in U2OS cells 
subjected to HS (dataset 2). The y-axis represents RPKM (reads per kb per million mapped 
reads). Boxplots (64) are shown without outliers. ∗∗∗P ≤ 10-16 by pairwise Wilcoxon signed-rank 
test. (B) Profile of HS-induced SUMO-2 peaks (dataset 2). Alignment of sequencing reads at 
13,390 HS-induced SUMO-2–binding sites. The y-axis represents reads per base per million 
reads. (C) Alignment of HS-induced SUMO-2–binding sites associated with HSPA1A, CHD4, 
RPS16, and ZNF331 in U2OS cells with DHSs from untreated HeLa-S3 cells, osteoblasts, 
IMR90 cells, and LNCaP cells (from ENCODE). Green arrows indicate the direction of 
transcription. Chr, chromosome. (D) Co-occurrence of HS-induced SUMO-2 peaks (n = 13390) 
and sites of enhanced chromatin accessibility (from ENCODE) 5 kb either side of the SUMO-2 
peaks calculated by IntervalStats. POLR3A and STAT3 (from ENCODE) are shown as negative 
controls. Enhanced chromatin accessibility datasets are derived from untreated HeLa-S3 cells. 
FAIRE, formaldehyde-assisted isolation of regulatory elements; DNaseI, DNaseI-seq; ChIP 
synthesis, compilation of transcription factor–binding sites identified by ChIP-seq experiments 
for various transcription factors. (E) Co-occurrence of HS-induced TSS-associated SUMO-2 
peaks only (n = 7325 peaks; TSS ± 2 kb). Details are as described for (D). 
 
Fig. 2. Genomic distribution of HS-induced SUMO-2 peaks and their relationship to active 
histone marks. (A) Left: Location of HS-induced SUMO-2–binding sites relative to the 
annotated protein-coding genome, including 2 kb upstream from the TSS, 2 kb downstream from 
the end of the gene, and intergenic sites (> 2 kb from any gene). Right: The distribution of 
annotations across the human genome is shown for comparison. (B) Alignment of HS-induced 
SUMO-2 peaks to the TSSs of protein-coding genes (dataset 2). A total of 7325 HS-induced 
SUMO-2 peaks map to a region spanning 2 kb either side of TSSs (n = 6290 peaks). The y-axis 
represents reads per base per million reads. (C) Co-occurrence of HS-induced SUMO-2 peaks (n 
= 13390) and histone modification marks within a region spanning 5 kb either side of a SUMO-2 
peak as calculated by IntervalStats. Histone modification data sets are derived from untreated 
HeLa-S3 cells. (D) Co-occurrence of HS-induced TSS-associated SUMO-2 peaks only (n = 7325 
peaks; TSS ± 2 kb). Details are as described for (C). (E) Alignment of HS-induced SUMO-2 
peaks with active histone modification marks at sites associated with EIF2S2 (left) and DEDD2 
(right). See (C) for histone datasets. 
 
Fig. 3. Relationship between HS-induced SUMO-2 occupancy and gene expression. (A) 
Functional analysis of HS TAP-SUMO-2 substrates (n = 755 HS TAP-SUMO-2 substrates) (17) 
and genes associated with HS SUMO-2 peaks (n = 8036 genes associated with HS SUMO-2 
peaks). A random gene set (n = 2500 genes) not associated with HS-induced SUMO-2 peaks 
served as a control. The dotted line indicates P = 0.05. (B) Venn diagram showing overlap 
between HS TAP-SUMO-2 substrates (n = 755 HS TAP-SUMO-2 substrates) and SUMO-2–
bound genes (n = 8036). (C) The relative abundances of mRNAs of genes that were either bound 
or not bound by SUMO-2 in untreated U2OS cells or in U2OS cells subjected to HS for 4 hours 
were measured by RNA-seq. Boxplots and P values were derived as described in Fig. 1A. Data 
are from three biological replicates. (D) Differential expression analysis of SUMO-2 target genes 
and non-SUMO-2 target genes in response to HS. Boxplots and P values were derived as 
described in Fig. 1A. Data are from three biological replicates. (E) Molecular and cellular 
function analysis of SUMO-2 target genes and non-SUMO-2 target genes upon HS. Dotted line 
denotes P = 0.05. (F) Effect of the siRNA-mediated depletion of Ubc9 on SUMO-2 target gene 
expression after HS. Cells were transfected with control siRNA or Ubc9-specific siRNA. Ninety-
six hours later, cells were left untreated or were subjected to HS for the indicated times before 
newly synthesized RNAs were labeled with 4-thiouridine and the indicated RNAs were 
quantified. (G) Effect of the siRNA-mediated depletion of Ubc9 on non-SUMO-2 target gene 
expression after HS. Cells were transfected with control siRNA or Ubc9-specific siRNA. Ninety-
six hours later, cells were left untreated or were subjected to HS for the indicated times before 
newly synthesized RNAs were labeled with 4-thiouridine and the indicated RNAs were 
quantified. Data in (F) and (G) are means ± SEM of three independent biological replicates. 
 
Fig. 4. Kinetics of the HS-induced recruitment of SUMO-2 to chromatin. (A) Time-course of 
the HS-induced conjugation of SUMO-2 to proteins. U2OS cells were left untreated or were 
subjected to HS for the indicated times, fractionated into cytoplasmic and nuclear extracts, and 
then analyzed by Western blotting with antibodies against the indicated targets. Western blots are 
representative of two independent experiments. (B) Time-course of the HS-induced recruitment 
of SUMO-2 to chromatin. U2OS cells were left untreated or were subjected to HS for the 
indicated times. SUMO-1 and SUMO-2 chromatin occupancy was analyzed by ChIP-RT-qPCR 
with primers specific for the regulatory regions of the indicated genes. Data are means ± SD of at 
least two independent experiments and were analyzed by GraphPad Prism software. (C) Effect of 
the depletion of PIAS proteins on the HS-induced recruitment of SUMO-2 to chromatin. U2OS 
cells were transfected with non-targeting siRNA (siCTRL), siRNAs specific for individual PIAS 
proteins, or a pool thereof. Transfections were repeated 48 hours after the initial transfection. 
Ninety-six hours after the initial transfection, the cells were left untreated or were subjected to 
HS for 30 min. The extent of recruitment of SUMO-2 to chromatin was analyzed as described 
for (B). Data are means ± SEM of six biological replicates derived from three independent 
experiments and were analyzed by GraphPad Prism software. 
 
Fig. 5. The HS-induced recruitment of SUMO to chromatin is part of the proteotoxic stress 
response. (A) U2OS cells were left untreated or were subjected to HS for 30 min and allowed to 
recover (rec) at 37°C for the indicated times before being exposed to a second round of HS for 
30 min (HS-rec-HS). The recruitment of SUMO-1 and SUMO-2 to chromatin was measured by 
ChIP-RT-qPCR analysis with primers specific for the regulatory regions of the indicated genes. 
Data are means ± SD of two biological replicates from two independent experiments. (B) SUMO 
conjugation during HS and recovery. U2OS cells were treated as described in (A), and where 
indicated, the HSP90 inhibitors 17-AAG or CCT018159 were added at the start of the recovery 
period. Cells were then fractionated into cytoplasmic and nuclear extracts before being analyzed 
by Western blotting with antibodies against the indicated targets. Western blots are 
representative of two independent experiments. (C) U2OS cells were left untreated or were 
treated with proteasome inhibitor MG132 for indicated times. Where indicated, cells were 
subjected to HS (30 min) and a two-hour recovery period before the MG132 was added (HS-rec-
MG132). 17-AAG was added at the start of the recovery period. Cells were then fractionated into 
cytoplasmic and nuclear extracts before being analyzed by Western blotting with antibodies 
against the indicated targets. Western blots are representative of two independent experiments. 
(D) The recruitment of SUMO-2 to chromatin in response to MG132-induced proteotoxic stress 
was determined as described in (A). (E) The recruitment of SUMO-2 to chromatin in response to 
L-canavanine-induced proteotoxic stress was determined as described in (A). Data in (D) and (E) 
are means ± SD of two biological replicates from two independent experiments. 
 
Fig. 6. The HS-induced recruitment of SENP6 to chromatin. (A to E) Time-course analysis 
of the HS-induced recruitment of SENP6 to chromatin. U2OS cells were left untreated or were 
subjected to HS for the indicated times. The recruitment of SENP6 to chromatin was analyzed by 
ChIP and RT-qPCR with primers specific for the regulatory regions of the indicated genes. 
Primers specific for a region 1800 bp upstream of the CHD4 regulatory region (CHD4-1800) 
were used as control. Data in (A) to (E) are means ± SEM of four biological replicates from two 
independent experiments and were analyzed by GraphPad Prism. 
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